Effects of atacicept on disease activity in patients with moderate to severe systemic lupus erythematosus: APRIL-SLE randomized trial

Eitemau Tebyg

• Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial)
  gan: Isenberg, David, et al.
  Cyhoeddwyd: (2015)
• Post Hoc Analysis of the Phase II/III APRIL‐SLE Study: Association Between Response to Atacicept and Serum Biomarkers Including BLyS and APRIL
  gan: Gordon, Caroline, et al.
  Cyhoeddwyd: (2016)
• Profile of atacicept and its potential in the treatment of systemic lupus erythematosus
  gan: Cogollo, Estafania, et al.
  Cyhoeddwyd: (2015)
• Efficacy and Safety of Rituximab in Moderately-to-Severely Active Systemic Lupus Erythematosus: The Randomized, Double-Blind, Phase II/III Systemic Lupus Erythematosus Evaluation of Rituximab Trial
  gan: Merrill, Joan T., et al.
  Cyhoeddwyd: (2010)
• Belimumab in systemic lupus erythematosus (SLE): evidence-to-date and clinical usefulness
  gan: Guerreiro Castro, Sara, et al.
  Cyhoeddwyd: (2017)